Early cancer trial halted after testing new drug combo
NCT ID NCT02997332
Summary
This early-stage study aimed to see if it was safe to add a new immunotherapy drug called durvalumab to a standard three-drug chemotherapy regimen for patients with advanced head and neck cancer that had not spread. The main goal was to find the safest dose for future testing and understand the side effects of this combination. The trial was terminated early and only enrolled 14 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.